CLDX Celldex Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development of therapeutic antibodies targeting mast cell biology for severe inflammatory and autoimmune diseases
• • New emphasis on bispecific antibody platform, highlighted by CDX-622 targeting TSLP and SCF with Phase 1 studies initiated in 2024-2026
• • Strategic shift toward building a fully integrated, commercial-stage biopharma company with potential for retaining full economic rights or forming partnerships
• • Phase 3 enrollment completed for Barzolvolimab in Chronic Spontaneous Urticaria; topline data expected Q4 2026
• • Notable sustained efficacy: over 40% of CSU patients maintained complete response at 76 weeks post-dosing with Barzolvolimab

Risk Factors

• • FDA regulatory delays from recent 43-day government shutdown Oct-Nov 2025 impacting review timelines
• • Global supply chain disruptions threatening clinical trial material supplies and contract manufacturing capacity
• • Clinical trial enrollment challenges due to patient recruitment difficulties risking costly delays or trial cancellations
• • Market competition risk from other monoclonal antibody developers with more advanced or approved therapies
• • $52.5M milestone payment under Kolltan merger may require dilutive stock issuance or additional debt funding

Management Discussion & Analysis

• • No revenue or YoY change disclosed; focus on clinical R&D for barzolvolimab and CDX-622
• • R&D expenses $245.1M in 2025 vs $163.6M in 2024 and $118.0M in 2023, driven by barzolvolimab program ($198.3M in 2025)
• • Barzolvolimab program best performing segment with $198.3M R&D spend; CDX-622 at $19.0M; no revenue or profit data provided
• • No cash flow, buybacks, dividends, or capex details disclosed in provided text
• • Management expects topline Phase 3 data for CSU indication in Q4 2026; key risk: lengthy, costly clinical trials, uncertain regulatory approvals, and capital needs

What are the latest CLDX SEC filings in 2026?

Celldex Therapeutics, Inc. (CLDX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did CLDX file its most recent 10-K annual report?

Celldex Therapeutics, Inc. (CLDX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view CLDX 10-Q quarterly reports?

Celldex Therapeutics, Inc. (CLDX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every CLDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has CLDX filed recently?

Celldex Therapeutics, Inc. (CLDX)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find CLDX insider trading activity (Form 4)?

SignalX aggregates every CLDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does CLDX file with the SEC?

Celldex Therapeutics, Inc. (CLDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CLDX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Celldex Therapeutics, Inc. (CLDX).

What is CLDX's SEC CIK number?

Celldex Therapeutics, Inc. (CLDX)'s SEC CIK (Central Index Key) number is 744218. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 744218 to look up all CLDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find CLDX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Celldex Therapeutics, Inc. (CLDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.